Biotechnology News and Research

RSS

Applied Biosystems' AmpFℓSTR MiniFiler PCR Amplification Kit receives NDIS approval

Applied Biosystems, part of Life Technologies Corporation today announced that its AmpFℓSTR® MiniFiler™ PCR Amplification Kit has been approved for inclusion in the National DNA Index System (NDIS), a United States Federal Bureau of Investigation database that facilitates the electronic comparison and exchange of DNA profiles between participating local, county, state, and federal law enforcement agencies and forensic laboratories.

21 Jan 2010

Pfizer and Auxilium Pharmaceuticals announce completion of European MAA validation phase for XIAFLEX

Pfizer Inc. and Auxilium Pharmaceuticals, Inc. today announced that Pfizer received notification from the European Medicines Agency that the Marketing Authorization Application (MAA) for XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, biologic for the treatment of Dupuytren’s contracture (a condition resulting in the contracture of the fingers into the palm), has completed the validation phase successfully. As a result, the scientific/technical review procedure commenced on 21 January 2010.

21 Jan 2010

MDS announces unaudited financial results for fiscal 2009

MDS Inc., a leading provider of products and services to the global life sciences markets, today reported preliminary and unaudited financial results for the three-month period ended October 31, 2009 and for the full 2009 fiscal year ended October 31, 2009. MDS intends to file financial results for fiscal 2009 on or before January 29, 2010.

From Danaher 21 Jan 2010

Benefits of NIH funding through the Recovery Act

In advance of the one-year anniversary of the Recovery and Reinvestment Act's enactment on February 17, twenty of the nation's leading research institutions, patient advocates and biomedical industry have released a detailed report on how Recovery Act funding of medical research through the National Institutes of Health (NIH) is at work across the country in the service of better health and a healthier economy.

21 Jan 2010

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

In a significant step toward restoring healthy blood circulation to treat a variety of diseases, a team of scientists at Weill Cornell Medical College has developed a new technique and described a novel mechanism for turning human embryonic and pluripotent stem cells into plentiful, functional endothelial cells, which are critical to the formation of blood vessels.

21 Jan 2010

New effort to produce standardized DNA parts for reducing development time of synthetic biology in labs

With seed money from the National Science Foundation (NSF), bioengineers from the University of California, Berkeley, and Stanford University are ramping up efforts to characterize the thousands of control elements critical to the engineering of microbes so that eventually, researchers can mix and match these "DNA parts" in synthetic organisms to produce new drugs, fuels or chemicals.

21 Jan 2010

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

BIO Ventures for Global Health, GlaxoSmithKline (GSK), and Alnylam announced today that the organizations are partnering to engage the global health community in using the powerful resources of the GSK and Alnylam Intellectual Property (IP) Pool.

21 Jan 2010

Quorum sensing offers a dynamic approach to increase sensitivity to external signals

Researchers at UC San Diego who last year genetically engineered bacteria to keep track of time by turning on and off fluorescent proteins within their cells have taken another step toward the construction of a programmable genetic sensor. The scientists recently synchronized these bacterial "genetic clocks" to blink in unison and engineered the bacterial genes to alter their blinking rates when environmental conditions change.

21 Jan 2010

Simulations Plus board authorizes renewed share repurchase program

Simulations Plus, Inc., the leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that its board of directors has authorized a renewed share repurchase program effective Monday, February 15, 2010.

21 Jan 2010

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

pSivida Corp., a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22.

21 Jan 2010

BARDA awards Duke University $3.7M to develop diagnostic test for detecting radiation exposure

Duke University has received a $3.7 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid and accurate genomic-based diagnostic test that can determine if a person has been exposed to radiation from a dirty bomb or nuclear attack. In the event that all option years are exercised by the government, Duke University could receive up to $43.6 million from the contract.

21 Jan 2010

NHC urges congress to continue work on meaningful healthcare reform

The National Health Council (NHC), an organization providing a united voice for the more than 133 million people with chronic diseases and disabilities and their family caregivers, today sent a letter to Congress urging the House and Senate to "continue working to accomplish the long-sought goal of health care reform."

21 Jan 2010

New class of HCV inhibitors discovered by Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the labs of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "Identification of a Novel Class of HCV Inhibitors". Published in the January 20th edition of Science and Translational Medicine, the research validates a domain, termed 4BAH2, within the non-structural protein (NS4B) of the HCV genome, as essential for HCV replication and describes the development of a high-throughput screen leading to the identification of small molecule inhibitors of 4BAH2.

21 Jan 2010

BIO commends GSK and Alnylam’s efforts to foster new therapies for neglected diseases

The Biotechnology Industry Organization (BIO) applauds the joint efforts of BIO members GlaxoSmithKline and Alnylam Pharmaceuticals to encourage research to accelerate medical therapies for neglected diseases and today’s announcement of the selection of BIO Ventures for Global Health (BVGH) as the administrator of the Intellectual Property (IP) Pool.

21 Jan 2010

InterMune prices public offering of newly issued common stock

InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.

21 Jan 2010

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled "Compositions and methods for enzymatic detachment of bacterial and fungal biofilms" by IP Australia (Australian Patent and Trademark Office).

21 Jan 2010

Targeted Genetics receives delisting notification from NASDAQ Stock Market

Targeted Genetics Corporation (the “Company”) today announced that it has received a written notice from the staff of The NASDAQ Stock Market (“NASDAQ”) informing the Company that trading of the Company’s common stock would be suspended prior to the open of business on Thursday, January 21, 2010, and that NASDAQ would initiate procedures to delist the Company’s common stock.

20 Jan 2010

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

20 Jan 2010

New white paper examines how PCR mycoplasma tests and analysis save time and money

Contamination by mycoplasmal organisms is an ever-present concern in biopharmaceutical manufacturing. Their properties make them ready sources of contamination, while rendering them difficult and time-consuming to detect. A new free white paper, examines how PCR mycoplasma tests and analysis, deployed by a cutting-edge laboratory, minimizes testing delays and enable safe, high-volume biopharmaceutical production.

20 Jan 2010

AMRI’s Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that AMRI’s high potency research laboratories and GMP-manufacturing facilities in Rensselaer, New York have met the criteria established under the SafeBridge program for “Potent Compound Safety Certification” and have been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients (“APIs”).

20 Jan 2010

Biotechnology News and Research

Applied Biosystems' AmpFℓSTR MiniFiler PCR Amplification Kit receives NDIS approval

Pfizer and Auxilium Pharmaceuticals announce completion of European MAA validation phase for XIAFLEX

MDS announces unaudited financial results for fiscal 2009

Benefits of NIH funding through the Recovery Act

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

New effort to produce standardized DNA parts for reducing development time of synthetic biology in labs

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

Quorum sensing offers a dynamic approach to increase sensitivity to external signals

Simulations Plus board authorizes renewed share repurchase program

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

BARDA awards Duke University $3.7M to develop diagnostic test for detecting radiation exposure

NHC urges congress to continue work on meaningful healthcare reform

New class of HCV inhibitors discovered by Eiger BioPharmaceuticals

BIO commends GSK and Alnylam’s efforts to foster new therapies for neglected diseases

InterMune prices public offering of newly issued common stock

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

Targeted Genetics receives delisting notification from NASDAQ Stock Market

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

New white paper examines how PCR mycoplasma tests and analysis save time and money

AMRI’s Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News